<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620357</url>
  </required_header>
  <id_info>
    <org_study_id>PTL903076</org_study_id>
    <nct_id>NCT03620357</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring &amp; Management In Type 2 Diabetes (T2D)</brief_title>
  <acronym>COMMITED</acronym>
  <official_title>Continuous Glucose Monitoring &amp; Management In Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control&#xD;
      using multiple oral agents are able to make lifestyle changes resulting in improved glycemic&#xD;
      control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning&#xD;
      modules versus self monitored blood glucose (SMBG) testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is referred to as &quot;Continuous Glucose Monitoring and Management in Type 2 Diabetes&quot;&#xD;
      also known as The COMMITED Study&quot; and will assess if patients with Type 2 diabetes (T2D) who&#xD;
      have suboptimal glycemic control using 2 or more multiple oral agents are able to make&#xD;
      lifestyle changes resulting in improved glycemic control by use of real-time continuous&#xD;
      glucose monitoring and targeted learning modules.&#xD;
&#xD;
      At time of enrollment, participants will undergo a run-in period of blinded CGM for a&#xD;
      duration of 10 days to collect baseline data. Baseline Patient Report Outcome (PRO) surveys&#xD;
      will be administered at the start of run-in.&#xD;
&#xD;
      The study design includes a run-in phase, a study phase and a follow up visit. During the&#xD;
      study phase, participants will be randomized into two groups - CGM Group or SMBG Group. For&#xD;
      the RT-CGM Group, the study comprises of 4 scheduled clinic visits at baseline (after&#xD;
      Run-In), week 4, week 8, and week 12 to collect data on episodic RT-CGM use. During these&#xD;
      visits, RT-CGM insertions will take place at baseline, week 4 and week 8 clinic visits, with&#xD;
      each wear period lasting a duration of 10 days. For the SMBG Group, the study comprises of 3&#xD;
      scheduled clinic visits at baseline (after Run-In), week 8 (to collect data on episodic&#xD;
      blinded CGM use) and week 12. CGM insertions will take place at week 8 with a wear period of&#xD;
      10 days. Both groups will have HbA1c collected at week 0 and week 12. The same PRO surveys&#xD;
      administered at start of run-in will be administered again at week 12. There will not be&#xD;
      therapeutic changes during the study phase unless needed for safety.&#xD;
&#xD;
      There will be phone/remote visits by a study site clinician at weeks 2, 6 and 10 in both&#xD;
      groups to review the SMBG or CGM data. During these remote visits, there will be discussions&#xD;
      about what the subjects have learned from their glucose monitoring and what the study&#xD;
      clinician has observed.&#xD;
&#xD;
      All subjects will be scheduled for a follow up visit at Month 9 to obtain local lab or POC&#xD;
      HbA1c. Diabetes medications (classifications only) will also be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">May 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, multicenter, two-arm pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>From baseline to Month 3 (Week 12)</time_frame>
    <description>The primary endpoint is defined as change in HbA1c (determined by local lab or POC results).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Continuous Glucose Monitor (CGM) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SMBG Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>CGM Group: Dexcom G6 CGM</description>
    <arm_group_label>Continuous Glucose Monitor (CGM) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SMBG</intervention_name>
    <description>SMBG Group: Blood Glucose Meter</description>
    <arm_group_label>SMBG Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          -  Age at least 30 years&#xD;
&#xD;
          -  Diagnosis of T2D treated with 2 or more oral anti-diabetic medications&#xD;
&#xD;
          -  HbA1c ≥ 7.8 and ≤10.5% by local lab or POC&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  Using insulin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Price, MD</last_name>
    <role>Study Director</role>
    <affiliation>DexCom, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes/Lipid Management and Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temecula Valley Endocrinology</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MODEL Clinical Research (Towson)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrine Associates, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Endocrinology</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Docs</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Research Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Manna Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

